Methods for detecting the presence of coronavirus-specific antibodies in a subject

Coronaviridae is a family of enveloped, positive-sense, single-stranded RNA viruses. The viral genome is 26–32 kilobases in length. In late December 2019, a new betacoronavirus SARS-CoV-2 has emerged in Wuhan China. The World Health Organization has named the severe pneumonia caused by this new coronavirus COVID-19 (for Corona Virus Disease 2019, WHO, 2020). To fight against the COVID-19 pandemic in a long term, in addition to the containment measures implemented in many countries, reliable diagnostic methods are highly desirable. In particular, the development and availability of tests for the detection and quantification of anti-SARS-CoV-2 antibodies in subjects with COVID-19 is of strong diagnostic interest. The present fulfils this need. In particular, the inventors developed an Adressable Laser Beads ImmunoAssay (ALBIA) method based on the use of particles conjugated with a coronaviral polypeptides (S1,S2, S2’, N, PL-Pro). More particularly, the inventors show that detection and titration of anti-SARS-Cov-2 Spike S1 IgG and IgM antibodies are feasible by said method.

Keywords: COVID19, Serology Test
Patent Application number: EP20 315 157.6 on 14/04/20
Publications:
Front Microbiol. 2020 Nov 26;11:603931. Drouot L et al. Evaluation of Humoral Immunity to SARS-CoV-2: Diagnostic Value of a New Multiplex Addressable Laser Bead Immunoassay. doi: 10.3389/fmicb.2020.603931.

Reference:

BIO20194-D1

Business Developper
contact
Pierre MAZOT
Pierre MAZOT
Business Developer
Patent filling date: 2020-04-14

You might also be interested in